

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request
Ein Cyf / Our Ref: 22-G-015

Please note that we have provided this information for the period April to June 2022.

You asked:

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:

Carboplatin (monotherapy or in combination with 5-FU)	<5*
Cisplatin (monotherapy or in combination with 5-FU)	15
Cetuximab with/without chemotherapy	0
Cetuximab with radiotherapy	0
Pembrolizumab monotherapy	<5*
Pembrolizumab with chemotherapy	0
Nivolumab	6
Docetaxel (monotherapy or in combination with 5-FU)	0
Fluorouracil (5FU)	0
Radiotherapy only	To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.
Other	<5*



2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

- **Total number of head and neck cancer patients**
- **Number of locally advanced head and neck cancer patients**
- **Number of unresectable recurrent and/or metastatic head and neck cancer patients**

I can confirm that this information is not held centrally. Our Pharmacy systems does not separate treatments by stage/type of cancer. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

Avelumab	0
Atezolizumab	8
Carboplatin with Gemcitabine	<5*
Carboplatin single or in any other combination	<5*
Cisplatin with Gemcitabine	7
Cisplatin single or in any other combination	0
Nivolumab	0
Pembrolizumab	0
Any other regimen including Paclitaxel	<5*
Any other chemotherapy regimen	<5*
Other active systemic anti-cancer therapy (please state)	0
Palliative care only	To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.



4. Does your Health Board participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Yes, in the time period specified the Health Board was taking part in the following trials;

- Compare - Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
- Torpedo - A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
- Pearl - PET-BASED ADAPTIVE RADIOTHERAPY CLINICAL TRIAL.

A total of 16 patients were recruited across all three trials in the time period specified.

*Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

